Cost-effectiveness analysis of tafolecimab in patients with hypercholesterolemia

LI Tong; ZHANG Xinyue; FENG Mengwen; FENG Zhen

doi:10.6039/j.issn.1001-0408.2025.22.11

您当前的位置：

首页 >

文章列表页 >

Cost-effectiveness analysis of tafolecimab in patients with hypercholesterolemia

更新时间：2025-11-25

- Cost-effectiveness analysis of tafolecimab in patients with hypercholesterolemia
- ZHONGGUO YAOFANG Vol. 36, Issue 22, Pages: 2815-2821(2025)
- 作者机构：
  
  1.徐州医科大学附属医院药学部，江苏徐州　221006
  2.复旦大学公共卫生学院，上海　200032
  3.徐州医科大学附属医院心血管内科，江苏徐州　221006
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.22.11
  CLC： R972+.6;R956
- Received：08 July 2025，
  
  Revised：2025-10-31，
  
  Accepted：31 October 2025，
  
  Published：30 November 2025
- 稿件说明：
移动端阅览
李彤,张新悦,冯梦文,等.托莱西单抗用于高胆固醇血症患者的成本-效果分析 ^Δ[J].中国药房,2025,36(22):2815-2821.

LI Tong,ZHANG Xinyue,FENG Mengwen,et al.Cost-effectiveness analysis of tafolecimab in patients with hypercholesterolemia[J].ZHONGGUO YAOFANG,2025,36(22):2815-2821.
李彤,张新悦,冯梦文,等.托莱西单抗用于高胆固醇血症患者的成本-效果分析 ^Δ[J].中国药房,2025,36(22):2815-2821. DOI： 10.6039/j.issn.1001-0408.2025.22.11.

LI Tong,ZHANG Xinyue,FENG Mengwen,et al.Cost-effectiveness analysis of tafolecimab in patients with hypercholesterolemia[J].ZHONGGUO YAOFANG,2025,36(22):2815-2821. DOI： 10.6039/j.issn.1001-0408.2025.22.11.

摘要

目的

评估托莱西单抗治疗高胆固醇血症的经济性，为优化高胆固醇血症管理策略、合理配置医疗资源提供依据。

方法

基于中国卫生体系视角，构建11种互斥健康状态的Markov转移队列模型，模拟目标患者的进展和预后。模型周期为1年，研究时限为30年。依据CREDIT系列临床试验数据设定模型状态间的转移概率，健康效用值及医疗成本参数来自统计年鉴和已发表文献。以质量调整生命年（QALY）作为健康产出评价指标，采用成本-效果分析法，分别计算在他汀类药物基础上联用托莱西单抗150 mg每2周注射1次（q2w）、450 mg每4周注射1次（q4w）、600 mg每6周注射1次（q6w）3种方案相对于对照方案（他汀类药物）的增量成本-效果比（ICER）。以中国1～3倍2024年人均国内生产总值（GDP）作为意愿支付阈值（WTP），贴现率为5%。通过单因素敏感性分析、概率敏感性分析及情境分析验证模型的稳健性。

结果

托莱西单抗150 mg q2w方案较对照方案的ICER为 235 827.73元/QALY，低于WTP（287 100元/QALY），具有一定经济性；而450 mg q4w和600 mg q6w方案相比于对照方案的ICER分别为329 498.24和318 630.51元/QALY，均高于WTP，不具有经济性。单因素敏感性分析显示，贴现率为关键影响因素。概率敏感性分析显示，在本研究设定的WTP下，托莱西单抗450 mg q4w和600 mg q6w方案具有经济学优势的概率分别为15.3%和22.4%，而150 mg q2w方案具有经济学优势的概率达85.2%。情境分析结果显示，模拟时限在5～30年内，托莱西单抗相较于对照方案的ICER逐步降低；托莱西单抗降价超过20%时，3种给药方案均具有经济性。

结论

在当前中国卫生体系视角下，与单用他汀类药物相比，托莱西单抗150 mg q2w方案的联用能够改善高胆固醇血症患者的健康结局，在现有WTP下具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of tafolecimab in patients with hypercholesterolemia， and provide support for optimizing management strategies for hypercholesterolemia and healthcare resource allocation.

METHODS

From the perspective of the Chinese healthcare system， an 11-state mutually exclusive Markov cohort model was developed to simulate disease progression and prognosis in the target population. The model cycle was set to one year， with a 30-year time horizon. Transition probabilities between health states were derived from the CREDIT series of clinical trials， while health utility values and medical cost parameters were sourced from the statistical yearbook and published literature. Quality-adjusted life years （QALYs） were used as the measure of health outcomes. Cost-effectiveness analysis was employed to calculate the incremental cost-effectiveness ratio （ICER） for three dosing regimens of tafolecimab [150 mg every 2 weeks （q2w）， 450 mg every 4 weeks （q4w）， and 600 mg every 6 weeks （q6w）] in combination with statins compared with control therapy （statins）. Using 1-3 times the per capita gross domestic product （GDP） of China in 2024 as willingness-to-pay threshold（WTP）， with a discount rate of 5%. Model robustness was assessed through one-way sensitivity analysis， probabilistic sensitivity analysis， and scenario analysis.

RESULTS

The 150 mg q2w regimen of tafolecimab yielded an ICER of 235 827.73 yuan/QALY， which was below the WTP （287 100 yuan/QALY）， indicating that the regimen was cost-effective. In contrast， the ICERs for the 450 mg q4w and 600 mg q6w regimens were 329 498.24 and 318 630.51 yuan/QALY， respec-tively， both exceeding the WTP and thus not cost-effective. One-way sensitivity analysis identified the discount rate as a key influencing factor. Probabilistic sensitivity analysis showed that under the WTP set in this study， the probabilities of cost-effectiveness for the 450 mg q4w and 600 mg q6w regimens were 15.3% and 22.4%， respectively， while the 150 mg q2w regimen had an 85.2% probability of being cost-effective. The situational analysis revealed that， over a simulated time horizon of 5 to 30 years， the ICER of tafolecimab was progressively reduced compared with the control regimen. When the price of tafolecimab was lowered by more than 20%， all three dosing regimens were demonstrated to be cost-effective.

CONCLUSIONS

Under the current Chinese healthcare system， compared with statin monotherapy， tafolecimab （150 mg q2w） combination improves health outcomes in patients with hypercholesterolemia， and is cost-effective given the current WTP.

关键词

Keywords

references

国家心血管病中心，中国心血管健康与疾病报告编写组 . 中国心血管健康与疾病报告2023概要 [J ] . 中国循环杂志， 2024 ， 39 （ 7 ）： 625 - 660 .

WANG Z W ， MA L Y ， LIU M B ， et al . Summary of the 2022 report on cardiovascular health and diseases in China [J ] . Chin Med J（Engl）， 2023 ， 136 （ 24 ）： 2899 - 2908 .

FERENCE B A ， GINSBERG H N ， GRAHAM I ， et al . Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic，epidemiologic，and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel [J ] . Eur Heart J ， 2017 ， 38 （ 32 ）： 2459 - 2472 .

SILVERMAN M G ， FERENCE B A ， IM K ， et al . Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions：a systematic review and meta-analysis [J ] . JAMA ， 2016 ， 316 （ 12 ）： 1289 - 1297 .

GENCER B ， MARSTON N A ， IM K ， et al . Efficacy and safety of lowering LDL cholesterol in older patients：a systematic review and meta-analysis of randomised controlled trials [J ] . Lancet ， 2020 ， 396 （ 10263 ）： 1637 - 1643 .

ZHANG M ， DENG Q ， WANG L H ， et al . Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults：a nationally representative survey of 163 641 adults [J ] . Int J Cardiol ， 2018 ， 260 ： 196 - 203 .

COHEN J C ， BOERWINKLE E ， Jr MOSLEY T H ， et al . Sequence variations in PCSK9，low LDL，and protection against coronary heart disease [J ] . N Engl J Med ， 2006 ， 354 （ 12 ）： 1264 - 1272 .

SABATINE M S ， GIUGLIANO R P ， KEECH A C ， et al . Evolocumab and clinical outcomes in patients with cardiovascular disease [J ] . N Engl J Med ， 2017 ， 376 （ 18 ）： 1713 - 1722 .

中国血脂管理指南修订联合专家委员会 . 中国血脂管理指南：2023 年 [J ] . 中国循环杂志， 2023 ， 38 （ 3 ）： 237 - 271 .

LIU H H ， LI S ， LI J J . Tafolecimab，a third monoclonal antibody for PCSK9 as the novel lipid-lowering drug around the world：a narrative review [J ] . Drugs ， 2025 ， 85 （ 5 ）： 627 - 642 .

HUO Y ， CHEN B J ， LIAN Q F ， et al . Tafolecimab in Chinese patients with non-familial hypercholesterolemia（CREDIT-1）：a 48-week randomized，double-blind，placebo-controlled phase 3 trial [J ] . Lancet Reg Health West Pac ， 2023 ， 41 ： 100907 .

CHAI M ， HE Y M ， ZHAO W ， et al . Efficacy and safety of tafolecimab in Chinese patients with heterozygous fami-lial hypercholesterolemia：a randomized，double-blind，placebo-controlled phase 3 trial（CREDIT-2） [J ] . BMC Med ， 2023 ， 21 （ 1 ）： 77 .

QI L T ， LIU D X ， QU Y L ， et al . Tafolecimab in Chinese patients with hypercholesterolemia（CREDIT-4）：a randomized，double-blind，placebo-controlled phase 3 trial [J ] . JACC Asia ， 2023 ， 3 （ 4 ）： 636 - 645 .

XIE W W ， SONG Y Y ， QIN X M ， et al . Cost-effectiveness of evolocumab in adult patients with atherosclerotic cardiovascular disease from Chinese healthcare perspective [J ] . Adv Ther ， 2023 ， 40 （ 2 ）： 489 - 503 .

FONAROW G C ， KEECH A C ， PEDERSEN T R ， et al . Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease [J ] . JAMA Cardiol ， 2017 ， 2 （ 10 ）： 1069 - 1078 .

赵晨颖 . 依洛尤单抗治疗动脉粥样硬化性心血管疾病的成本效果分析 [D ] . 石家庄：河北医科大学， 2021 .

COLLABORATION C T T ， BAIGENT C ， BLACKWELL L ， et al . Efficacy and safety of more intensive lowering of LDL cholesterol：a meta-analysis of data from 170 000 participants in 26 randomised trials [J ] . Lancet ， 2010 ， 376 （ 9753 ）： 1670 - 1681 .

WILSON P W F ， SR R D ， BHATT D L ， et al . An international model to predict recurrent cardiovascular disease [J ] . Am J Med ， 2012 ， 125 （ 7 ）： 695 - 703.e1 .

DANESE M D ， PEMBERTON-ROSS P ， CATTERICK D ， et al . Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom [J ] . Eur J Prev Cardiol ， 2021 ， 28 （ 3 ）： 335 - 343 .

国家卫生健康委 . 2023中国卫生健康统计年鉴 [EB/OL ] .（ 2025-01-24 ）[ 2025-06-25 ] . https：//zs.kaipuyun.cn/s?token=&siteCode=bm24000006&searchWord=%E5%B9% B4%E9%89%B4&button= https://zs.kaipuyun.cn/s?token=&siteCode=bm24000006&searchWord=%E5%B9%B4%E9%89%B4&button= .

沈瑛莹 . 瑞舒伐他汀在心血管疾病一级预防的药物经济学评价 [D ] . 沈阳：中国医科大学， 2021 .

WANG L ， WU Y Q ， TANG X ， et al . Profile and correlates of health-related quality of life in Chinese patients with coronary heart disease [J ] . Chin Med J（Engl）， 2015 ， 128 （ 14 ）： 1853 - 1861 .

MATZA L S ， STEWART K D ， GANDRA S R ， et al . Acute and chronic impact of cardiovascular events on health state utilities [J ] . BMC Health Serv Res ， 2015 ， 15 ： 173 .

KAZI D S ， MORAN A E ， COXSON P G ， et al . Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or athero-sclerotic cardiovascular disease [J ] . JAMA ， 2016 ， 316 （ 7 ）： 743 - 753 .

刘国恩，胡善联，吴久鸿，等 . 中国药物经济学评价指南 [M ] . 北京：中国市场出版社， 2020 ： 27 .

WAN Y S ， LIU J Y ， ZHAN X L ， et al . Cost-effectiveness and price threshold analysis of tafolecimab in Chinese patients with elevated LDL cholesterol despite statin therapy [J ] . Am J Cardiovasc Drugs ， 2025 ， 25 （ 4 ）： 547 - 561 .

ARRIETA A ， HONG J C ， KHERA R ， et al . Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers：insights derived from the FOURIER trial [J ] . JAMA Cardiol ， 2017 ， 2 （ 12 ）： 1369 - 1374 .

KODERA S ， MORITA H ， KIYOSUE A ， et al . Cost-effectiveness of PCSK9 inhibitor plus statin in patients with triple-vessel coronary artery disease in Japan [J ] . Circ J ， 2018 ， 82 （ 10 ）： 2602 - 2608 .

KONGPAKWATTANA K ， ADEMI Z ， CHAIYASOTHI T ， et al . Cost-effectiveness analysis of non-statin lipid-modifying agents for secondary cardiovascular disease prevention among statin-treated patients in Thailand [J ] . Pharmacoeconomics ， 2019 ， 37 （ 10 ）： 1277 - 1286 .

FONAROW G C ， VAN HOUT B ， VILLA G ， et al . Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease [J ] . JAMA Cardiol ， 2019 ， 4 （ 7 ）： 691 - 695 .

MOHIUDDIN S G ， WARD M E ， HOLLINGWORTH W ， et al . Cost-effectiveness of routine monitoring of long-term conditions in primary care：informing decision mo-delling with a systematic review in hypertension，type 2 diabetes and chronic kidney disease [J ] . Pharmacoecon Open ， 2024 ， 8 （ 3 ）： 359 - 371 .

HULTKRANTZ L . Discounting in economic evaluation of healthcare interventions：what about the risk term? [J ] . Eur J Health Econ ， 2021 ， 22 （ 3 ）： 357 - 363 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomic evaluation of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy

Pharmacoeconomic evaluation of trastuzumab deruxtecan versus chemotherapy in the second-line treatment of advanced breast cancer with HER-2 low expression

Pharmacoeconomics of ivabradine in the treatment of CHF in the context of “Quadruple Therapy”

Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction

Cost-effectiveness of regorafenib for hepatocellular carcinoma after failure of sorafenib

Related Author

XIA Runan

DI Panpan

ZHAO Mengmeng

ZHANG Pengcheng

HOU Yashen

ZHANG Hong

WU Wei

LIANG Hai

Related Institution

Dept. of Pharmacy， the People’s Hospital of Bozhou

Breast Center， the Fourth Hospital of Hebei Medical University

Dept. of Clinical Pharmacology， the Fourth Hospital of Hebei Medical University

Dept. of Pharmacy， the Fourth Hospital of Hebei Medical University

Dept. of Cardiology， Nanjing Drum Tower Hospital

⁰